Bortezomib-induced histiocytoid Sweet syndrome - 08/08/11
Doi : 10.1016/j.jaad.2008.09.007
Jenny E. Murase, MD a, b, ⁎ 
, Jashin J. Wu, MD c, Ivan Theate, MD d, Gary W. Cole, MD e, Ronald J. Barr, MD f, Senait W. Dyson, MD e
, Jashin J. Wu, MD c, Ivan Theate, MD d, Gary W. Cole, MD e, Ronald J. Barr, MD f, Senait W. Dyson, MD e a Department of Dermatology, University of California, San Francisco, California
b Palo Alto Foundation Medical Group, Mountain View, California
c Department of Dermatology, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, California
d Department of Anatomic Pathology, Cliniques Universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium
e Department of Dermatology, University of California, Irvine, California
f Laguna Pathology Medical Group, Laguna Beach, California
Reprint requests: Jenny E. Murase, MD, 701 E El Camino Real, Mountain View, CA 94040.Abstract |
Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as “histiocytoid Sweet syndrome.”
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
© 2008
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 60 - N° 3
P. 496-497 - mars 2009 Retour au numéro
Article précédent
- Tinea capitis mimicking cicatricial alopecia: What host and dermatophyte factors lead to this unusual clinical presentation?
- Paradi Mirmirani, Andrea Willey, Sarah Chamlin, Ilona J. Frieden, Vera H. Price
- Glossitis with linear lesions: An early sign of vitamin B12 deficiency
- Jordi Graells, Rosa Maria Ojeda, Cristina Muniesa, Jesus Gonzalez, Jose Saavedra
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?